中国重汽(000951.SZ)披露定增情况:鹏华基金、诺德基金及UBS AG等等参投
格隆汇 3 月 11日丨中国重汽(000951.SZ)发布非公开发行情况报告书暨上市公告书,结合首轮认购时的获配情况和追加认购的结果,此次发行最终获配发行对象共计23名,发行价格为29.82元/股,此次发行股票数量为168,111,600股,募集资金总额约50.13亿元。此次发行最终确定的发行对象及获配股数、获配数量、获配金额情况如下:


此次非公开发行新增股份168,111,600股,发行价格为29.82元/股,将于2021年3月15日在深圳证券交易所上市。
此次发行中,投资者认购的股票限售期为6个月,可上市流通时间为2021年9月15日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.